Executive Director
Eli Lilly and Company, Inc.
Indianapolis, Indiana, United States
Immunogenicity Risk Assessment: Are Preclinical Methods Informative? (S03)
Monday, November 18, 2024
9:00 AM – 12:00 PM CT
HESI/AAPS Reference Panel for Preclinical Immunogenicity Risk Assessment (S03-1)
Monday, November 18, 2024
9:00 AM – 9:20 AM CT